These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 20799464)

  • 1. Regulation of allergenic products in the United States: the promise and problem of adjuvants in allergen immunotherapy.
    Rabin RL
    Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():219-22; discussion 223. PubMed ID: 20799464
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvants and vector systems for allergy vaccines.
    Moingeon P; Lombardi V; Saint-Lu N; Tourdot S; Bodo V; Mascarell L
    Immunol Allergy Clin North Am; 2011 May; 31(2):407-19, xii. PubMed ID: 21530828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of allergen immunotherapy practice patterns in the United States and Europe.
    Cox L; Jacobsen L
    Ann Allergy Asthma Immunol; 2009 Dec; 103(6):451-59; quiz 459-61, 495. PubMed ID: 20084837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Legal status and regulation of allergenic products in the United States.
    Menzies S; Huynh S; Rabin RL
    Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2013; 97():9-14. PubMed ID: 24912306
    [No Abstract]   [Full Text] [Related]  

  • 5. Sublingual immunotherapy and subcutaneous immunotherapy: issues in the United States.
    Greenberger PA; Ballow M; Casale TB; Platts-Mills TA; Sampson HA
    J Allergy Clin Immunol; 2007 Dec; 120(6):1466-8. PubMed ID: 17936891
    [No Abstract]   [Full Text] [Related]  

  • 6. Nanoparticulate adjuvants and delivery systems for allergen immunotherapy.
    De Souza Rebouças J; Esparza I; Ferrer M; Sanz ML; Irache JM; Gamazo C
    J Biomed Biotechnol; 2012; 2012():474605. PubMed ID: 22496608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase I/IIa study.
    Pfaar O; Barth C; Jaschke C; Hörmann K; Klimek L
    Int Arch Allergy Immunol; 2011; 154(4):336-44. PubMed ID: 20975285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of allergen products in Japan.
    Teshima R
    Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():224-9. PubMed ID: 20799465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological mechanisms of allergen-specific immunotherapy.
    Larché M; Akdis CA; Valenta R
    Nat Rev Immunol; 2006 Oct; 6(10):761-71. PubMed ID: 16998509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Business barriers slowing the pace of cancer immunotherapy research and development.
    Tuma RS
    J Natl Cancer Inst; 2007 Nov; 99(21):1570-3. PubMed ID: 17971521
    [No Abstract]   [Full Text] [Related]  

  • 11. The future of sublingual immunotherapy.
    Marcucci F; Duse M; Frati F; Incorvaia C; Marseglia GL; La Rosa M
    Int J Immunopathol Pharmacol; 2009; 22(4 Suppl):31-3. PubMed ID: 19944008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Will sublingual immunotherapy become an approved treatment method in the United States?
    Cox L; Compalati E; Canonica W
    Curr Allergy Asthma Rep; 2011 Feb; 11(1):4-6. PubMed ID: 20976576
    [No Abstract]   [Full Text] [Related]  

  • 13. Preparing and mixing allergen vaccines.
    Nelson HS
    Clin Allergy Immunol; 2004; 18():457-79. PubMed ID: 15042929
    [No Abstract]   [Full Text] [Related]  

  • 14. Allergen-related approaches to immunotherapy.
    Rolland JM; Gardner LM; O'Hehir RE
    Pharmacol Ther; 2009 Mar; 121(3):273-84. PubMed ID: 19111571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eyes on new product development.
    Novack GD
    J Ocul Pharmacol Ther; 2013 Oct; 29(8):701. PubMed ID: 24073621
    [No Abstract]   [Full Text] [Related]  

  • 16. European allergen extract units and potency: review of available information.
    Larenas-Linnemann D; Cox LS;
    Ann Allergy Asthma Immunol; 2008 Feb; 100(2):137-45. PubMed ID: 18320915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of immunotherapy using various updosing schedules of a new SCIT product with an optimised allergen/aluminium hydroxide ratio.
    Jung K
    Allergy; 2011 Jul; 66 Suppl 95():41-3. PubMed ID: 21668852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Management and results of immunotherapy in the adult].
    Palma-Carlos AG
    Allergol Immunopathol (Madr); 1981; Suppl 9():174-6. PubMed ID: 6219555
    [No Abstract]   [Full Text] [Related]  

  • 19. Maintenance dosing for sublingual immunotherapy by prominent European allergen manufacturers expressed in bioequivalent allergy units.
    Larenas-Linnemann D; Esch R; Plunkett G; Brown S; Maddox D; Barnes C; Constable D
    Ann Allergy Asthma Immunol; 2011 Nov; 107(5):448-458.e3. PubMed ID: 22018618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of standardized extracts in allergen immunotherapy.
    Nelson HS
    J Allergy Clin Immunol; 2000 Jul; 106(1 Pt 1):41-5. PubMed ID: 10887303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.